Zofran Lawsuit Claims Exposure To Drug Caused Infant Girl’s Fatal Heart Defect

December 10, 2015 – – ZofranLegal.com reports on another tragic lawsuit filed against pharmaceutical conglomerate GlaxoSmithKline in reference to their anti-nausea drug Zofran. The complaint alleges that exposure to the drug while in the womb caused a baby girl to develop fatal heart defects, and, ultimately, to pass away at only 11 weeks of age.

Details found within the documents of the suit state that the baby’s mother was prescribed Zofran to combat her morning sickness nausea during her first trimester of pregnancy. The first trimester also happens to be a time when the fetus’ heart does much of its tissue development.

Months later, the mother gave birth to a baby girl with her heart on the wrong side of her body. Additionally, the heart had several major defects which required the infant to be placed on life support as she awaited a heart transplant. Despite the efforts of the medical team, after spending 11 weeks in the NICU, the infant girl died due to her defects.

Her mother’s lawsuit was filed in the United States District Court for the State of Tennessee in the Middle District of Nashville under case number 3:15-cv-00958. Since its initial filing, the case has been transferred to Boston, Massachusetts to become part of a multidistrict litigation with many similar lawsuits.

Across the nation, over 160 mothers have now stepped forward alleging that exposure to Zofran caused their babies to develop a range of serious congenital defects. In these lawsuits, birth defects most commonly noted are: cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, and kidney defects.

One of the topics most commonly discussed by plaintiffs involved in the Zofran MDL is the fact that the drug was never FDA-approved to treat expectant mothers, or tested for safety on this consumer group. The U.S. Food and Drug Administration instead specifically approved Zofran to treat patients suffering from nausea and vomiting episodes after undergoing chemotherapy, radiation therapy, or anesthesia. Despite this fact, however, Zofran manufacturer GlaxoSmithKline marketed their drug “off-label” to pregnant women and Ob/Gyn’s nation-wide as a morning sickness treatment. Subsequently, it is now prescribed “off-label” to an estimated 1 million pregnant mothers each year.

As the cases involved in the Zofran MDL (MDL number 2657) await trial, many expect that others will continue to be filed. The attorneys at Monheit Law believe that it is likely that many other families are eligible to file Zofran birth defect lawsuits of their own, and may be entitled to significant compensation. They are currently offering free consultations to those who used Zofran while pregnant and subsequently gave birth to infants with congenital defects.

To obtain additional information on Zofran lawsuits, or to ask questions, contact Michael Monheit, Esq. by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60006205